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Ovarian cancer is a major cause of death among gynecological cancers and its etiology
is still unclear. Currently, the two principle obstacles in treating this life threatening dis-
ease are lack of effective biomarkers for early detection and drug resistance after initial
chemotherapy. Similar to other cancers, the initiation and development of ovarian cancer
is characterized by disruption of oncogenes and tumor suppressor genes by both genetic
and epigenetic mechanisms. While it is well known that it is challenging to treat ovarian
cancer through a genetic strategy due in part to its heterogeneity, the reversibility of epi-
genetic mechanisms involved in ovarian cancer opens exciting new avenues for treatment.
The epigenomics of ovarian cancer has therefore become a rapidly expanding ﬁeld leading
to intense investigation. A review on the current status of the ﬁeld is thus warranted. In
this analysis, we will evaluate the current status of epigenomics of ovarian cancer and
will include epigenetic mechanisms involved in ovarian cancer development such as DNA
methylation, histone modiﬁcations, and non-coding microRNA. Development of biomark-
ers, the epigenetic basis for drug resistance and improved chemotherapy for ovarian cancer
will also be assessed. In addition, the potential use of natural compounds as epigenetic
modulators in chemotherapy shows promise in moving to the forefront of ovarian cancer
treatment strategies.
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INTRODUCTION
OVERVIEW OF OVARIAN CANCER
Ovarian cancer has the highest mortality rate among reproductive
cancers and is the leading cause of gynecologic cancer death. The
ovaries contain three types of tissue: germ, stromal, and epithe-
lial cells. Germ cells and stromal cells are inside of the ovary,
while epithelial cells are on the surface of the ovary. Germ cells
can make eggs, and stromal cells produce most of the female
hormones (estrogen and progesterone). The epithelium is the tis-
sue where most ovarian cancers arise. Ovarian cancer is classiﬁed
into several stages according to the American Joint committee on
Cancer/Tumor Node Metastasis (AJCC/TNM) and International
Federation of Gynecology and Obstetrics (FIGO) staging systems
which are based on how far the cancer has spread. In stages I and II,
the tumor is conﬁned to the ovaries, while there is local metastasis
(usually lymph) in stage III and there is distal organ metastases in
stage IV (Yarbro et al., 1999).
The etiology of ovarian cancer is still not clear. However, previ-
ous epidemiology studies indicate that for sporadic ovarian cancer,
the younger the individuals are when they have their ﬁrst child
and the more children they have, the less the risk of suffering
from ovarian cancer (Chen and Karlan, 1998). A hypothesis has
been proposed based on these epidemiology studies, that is, too
much wound repair after ovulation may contribute to the ovarian
tumorigenesis processes (Roett and Evans, 2009).
Due to the atypical syndrome of the early stage of ovarian
cancer, it is difﬁcult to diagnose in its early stages. By the time
most ovarian cancers are diagnosed, they are already at stage III
or IV. The two most signiﬁcant obstacles to the effective treatment
of ovarian cancers are the lack of early diagnostic markers and
the development of drug resistance after therapeutic treatment
of advanced disease. Ovarian cancer screening with transvaginal
ultrasound (TVU) and CA125 was evaluated in the Prostate, Lung,
Colorectal, andOvarian (PLCO) trial, however, it was revealed that
the predictive value of both tests was relatively low (Buys et al.,
2005). Increasing evidence indicates that epigenetic mechanisms
may play a major role in the development of ovarian cancer.
EPIGENETIC MODIFICATIONS IN CANCER
The epigenome is deﬁned as the mechanisms that regulate all
the genes expression without alteration of the DNA sequence
(Bernstein et al., 2007). These epigenetic mechanisms include
DNA methylation, histone modiﬁcation, and microRNA (miR-
NAs) expression which are known to regulate gene expression
in cancer cells. DNA methylation is characterized by transfer-
ring of a methyl moiety to cytosine at the 5-carbon (C5) position
by enzymes known as DNA methyltransferases (DNMTs). DNA
methylation can regulate gene transcription by recruiting methyl
CpG-binding proteins and therefore regulate chromatin status.
Typically, DNA hypermethylation could silence genes (e.g., tumor
suppressors) due to recruitment of repressors and further lead to
chromatin condensation (Herceg, 2007).
Histone modiﬁcations are characterized by covalent modiﬁ-
cation of the N-terminal tails of core of histones (H2A, H2B,
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H3, and H4) including acetylation,methylation, phosphorylation,
biotinylation, and ubiquitination (Feinberg et al., 2006; Hassan
and Zempleni, 2006; Doi et al., 2009). Based on studies focused
on the biological signiﬁcance of these modiﬁcations, concepts like
“histone code”and“histone language”have been proposed (Oliver
and Denu, 2011). Acetylation has been the most studied in cancer
among all these histone modiﬁcations. Histone acetyltransferases
(HATs) are responsible for the acetylation of the lysine residues
of histones (Turner, 2000), while histone deacetylases (HDACs)
can remove the acetyl moieties (Mottet and Castronovo, 2008;
Choudhuri et al., 2010). Histones acetylation generates an open
conformation of chromatin which is accessible to transcription
regulators, leading to the promotion of gene expression. More-
over HDACs can remove acetyl moieties from acetylated sites in
non-histone proteins thereby adding another layer of regulation
on cellular activities (Marson, 2009).
Non-coding miRNAs are regulatory RNAs that are 20–30
nucleotides in length that match the 3′ untranslated regions of
target mRNAs. miRNAs can inhibit mRNA translation or degrade
mRNA (Ducasse and Brown, 2006; Guil and Esteller, 2009; Lujam-
bio et al., 2010). miRNAs target multiple protein-coding tran-
scripts and are known to cause posttrancriptional gene down-
regulation and regulate a number of genes (Jones and Baylin,
2007). While miRNAs are tightly regulated in normal cells, in
cancer cells miRNAs are vastly deregulated (Veeck and Esteller,
2010). Additionally,miRNA proﬁles are being used to classify can-
cers and the misexpression of miRNAs is associated with cancer
development (Iorio et al., 2010;Veeck and Esteller, 2010). A global
down-regulation of miRNAs in multiple tumor tissues has also
been observed (Lu et al., 2005).
EPIGENOMIC MECHANISMS ON THE DEVELOPMENT OF
OVARIAN CANCER
ROLE OF DNA METHYLATION IN THE DEVELOPMENT OF OVARIAN
CANCER
The genome contains a wealth of CpG dinucleotides and the cyto-
sine in CpG dinucleotides can be methylated by DNMTs. Some of
the methylated CpGs are located in the centromere and subtelom-
eric regions and can also be found in repeated sequences, such as
Alu and LINEs sequences. Many CpGs in euchromatin are located
in the promoters of genes and when present are termed CpG
islands (CGIs). Themethylation status of CGIs is often under strict
regulation during cell differentiation, which constitutes one of the
basic concepts of epigenetics. The abnormal methylation status
can cause disorders in gene expression, thus leading to certain
diseases, including cancer. Hypermethylation is usually associated
with gene silencing, while hypomethylation is generally associ-
ated with gene expression. In cancer cells, CGI methylation has
been identiﬁed as a major cause of silencing of tumor suppres-
sor genes (TSGs), while CGI demethylation has been recognized
as a common mechanism involved in the activation of onco-
genes. CGI hypomethylation in the centromere and subtelomeric
regions have also been implicated in causing genomic instability
(GI) leading to chromosomal translocations and gene disruption
through the reactivation of endoparasitic sequences (Walsh et al.,
1998; Gaudet et al., 2003; Esteller and Almouzni, 2005). In ovar-
ian cancer, satellite DNA hypomethylation is increased compared
to normal tissues and this is more pronounced in advanced stages
than in early stages of ovarian cancer (Widschwendter et al., 2004).
TSGs include DNA mismatch repair genes such as hMLH1, cell
cycle-related genes such as p16, p21, and p27, and genes involved
in signal transduction (e.g., PTEN). Typically, epigenetic change of
certain genes involved in DNA mismatch repair could lead to GI.
This would further trigger abnormal expression of other tumor-
related genes through mutation or epigenetic mechanisms, which
is consistent with the “drivers” and “passengers” mutation theory.
In the theory, “drivers” refers to those genes after mutation that
can confer advantageous biological phenotypes, while “passen-
gers” refers to those mutations that reﬂect the general increased
mutability of tumor cell genomes due to mutation of “drivers”
(Weinberg, 2008).
In ovarian cancer, a number of TSGs have been found to
undergo hypermethylation (Table 1). As one of the genes that
is involved in inherited ovarian cancer, the promoter of BRCA1
is hypermethylated in sporadic cases of ovarian cancer (Baldwin
et al., 2000), which leads to the silencing of this gene in these
tumors (Wilcox et al., 2005). Consistent with the aforementioned
“drivers” and “passengers” mutation theory, silencing of BRCA1
together with other DNA repair genes, such as hMLH1 (Strathdee
et al., 1999), increase the chance of mutation of other genes related
to ovarian cancer cell proliferation by both genetic and epigenetic
approaches (Esteller, 2000),which further confers a growth advan-
tage to cancer cells. Other genes that can be silenced by promoter
hypermethylation in ovarian cancer include genes involved in cell
cycle regulation and genes that promote apoptosis such as LOT1,
DAPK, TMS1/ASC, and PAR-4.
In a recent study conducted by Matsumura et al. (2011)
microarray analysis of genome-wide changes in gene expression
was applied to 39 cell lines and 17 cultured primary ovarian cancer
specimens treatedwithDNAhypomethylating agents. In total, 378
candidate methylated genes contributing to ovarian cancer were
identiﬁed and anumber of genes involved in theTGF-beta pathway
were found to be regulated by methylation in ovarian cancer (Mat-
sumura et al., 2011).Adistinct gene cluster strongly correlatedwith
TGF-beta pathway activity that discriminates patients based on
age. This was generated by using the 378 genes through hierarchi-
cal clustering of ovarian cancers, which suggests that suppression
of TGF-beta signaling is caused by accumulation of age-related
epigenetic modiﬁcations.
Studies in this regard not only reveal gene regulation net-
works, but also provide information on the potential cause of
complicating diseases, such as cancer. Clinically, it can lead to dis-
covery of novel biomarkers and therapeutic targets; it can also lay
the foundation for personalized medicine that is tailored to each
individual’s genome and epigenomic status (Figure 1).
ROLE OF HISTONE MODIFICATIONS IN THE DEVELOPMENT OF OVARIAN
CANCER
Another major epigenetic mechanism involved in gene expres-
sion is histone modiﬁcation. These modiﬁcations include acety-
lation, methylation, and phosphorylation. Genes involved in cell
cycle regulation, such as cyclinB1 (Valls et al., 2005), p21 (Richon
et al., 2000), and ADAM19 (Chan et al., 2008) have been indi-
cated to be regulated by histone modiﬁcation. Overexpression of
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Table 1 |Tumor suppressor genes (TSGs) regulated by epigenetic mechanisms in ovarian cancer.
Gene name Pathway Mechanisms Reference
BRCA1 DNA damage response Hypermethylation Magdinier et al. (1998)
hMLH1 DNA mismatch repair Hypermethylation Strathdee et al. (1999)
CDKN2A (p16) Cell cycle checkpoint Hypermethylation Abou-Zeid et al. (2011)
CDKN1A (p21) Cell cycle checkpoint Histone modiﬁcation Takai and Narahara (2010)
LOT1 Apoptosis Hypermethylation and histone modiﬁcation Abdollahi et al. (2003)
DAPK Apoptosis Hypermethylation Collins et al. (2006)
TMS1/ASC Apoptosis Hypermethylation and histone deacytelation Terasawa et al. (2004)
RASSF1A Microtubule stability Hypermethylation Yoon et al. (2001)
GATA4 Maintenance of cell differentiation H3, H4 hypoacetylation Caslini et al. (2006)
GATA6 Maintenance of cell differentiation H3, H4 hypoacetylation Caslini et al. (2006)
PTEN PI3K/Akt Hypermethylation and up-regulation of miR-214 Schöndorf et al. (2004); Yang et al. (2008b)
APC Wnt/β-catenin Hypermethylation Makarla et al. (2005)
FIGURE 1 | Function of epigenomic studies in cancer prevention.
Epigenomic analyses of cancer could provide novel epigenetic
biomarkers which can serve for cancer risk evaluation, early detection,
prognosis, and chemotherapy response prediction. Studies of this nature
could also provide novel epigenetic therapy targets. In addition, genetic
analysis could contribute to these processes. Taken together, epigenomic and
genetic analyses could promote a personalized treatment for the optimal
beneﬁts to cancer patients.
the cancer-promoting genes claudin-3 and claudin-4 in ovarian
cancer is associated with loss of trimethylated histone 3 lysine
27 (H3K27me3) (Kwon et al., 2010). A protein, osteoprotegerin
(OPG), reportedly can inhibit cancer cell growth through apop-
totic mechanisms, and its gene may be silenced in ovarian cancer.
The loss of OPG gene expression correlates with reduced histone
3 lysine 4 trimethylation (H3K4me3) and increased H3K27me3
(Lu et al., 2009). GATA4 and GATA6 gene silencing also correlated
with hypoacetylation of histones H3 and H4 and loss of H3K4me3
at their promoters in ﬁve epithelial ovarian carcinoma cell lines
(Caslini et al., 2006) and only treatment with the HDAC inhibitor
(HDACIs), trichostatin A (TSA) can re-express these genes in the
ovarian cancer cells.
ROLE OF miRNAs IN THE DEVELOPMENT OF OVARIAN CANCER
microRNA is another epigeneticmechanism that often contributes
to regulation of gene expression and miRNAs can participate in
cancer progression by regulating expression of oncogenes or TSGs.
In ovarian cancer, miR-187 has been shown to inhibit its progres-
sion by down-regulating Dab2, which may promote tumor pro-
gression in advanced cancers through epithelial-to-mesenchymal
transition (EMT) (Chao et al., 2011). Additionally, ovarian tumors
were found to have down-regulated miR-100 and miRNA let-7i
and up-regulated miR-199a, miR-200a, and miR-214 (Iorio et al.,
2007;Yang et al., 2008a,c). Speciﬁcally,up-regulationof miR-214 in
ovarian cancer can induce the degradation of PTEN mRNA which
leads to activation of Akt pathway (Yang et al., 2008b). miRNAs
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have also been shown to regulate the apoptosis pathway in ovarian
cancer (Mezzanzanica et al., 2011).
OVARIAN CANCER BIOMARKER IDENTIFICATION AT THE EPIGENOMIC
LEVEL
Biomarkers are those biological molecules that could be used as
markers for diagnostic, prognostic, or therapeutic purposes. Bio-
markers that can represent the early stages of ovarian cancer are of
signiﬁcant importance for early detection of the disease due to its
atypical syndrome.Also, biomarkers can be used for better stratiﬁ-
cation of ovarian cancer subtypes for individualized treatment. So
far only two biomarkers of protein origin (CA125 and HE4) have
been approved by the FDA for monitoring ovarian cancer (Moore
et al., 2010). However, benign gynecological and medical condi-
tions such as endometriosis, congestive heart failure, and cirrhosis
can also have elevated CA125 levels, and elevated serum HE4 level
was only related to the advanced stage of epithelial ovarian cancer.
More speciﬁc and early detection biomarkers are sorely needed. As
one of the basic elements of epigenetic mechanisms, DNA methy-
lation has been recognized as a potential ideal biomarker due to its
stability compared with RNA and protein, sensitivity of detection
by PCR, the possibility of localization to a speciﬁc gene region and
potential of development as a high-throughput screening method
speciﬁc for cancer detection (Ahluwalia et al., 2001; Laird, 2003;
Anglim et al., 2008).
Epigenetic mechanisms as main players in cancer develop-
ment are emerging as attractive targets for characterizing reliable
biomarkers of ovarian cancer. Due to inaccessibility of ovaries
through a non-invasive strategy, association between methylation
of certain genes in DNA isolated from blood and cancer on ovaries
can improve the diagnosis of ovarian cancer in a non-invasive
manner. Hypermethylation of a number of TSG promoters has
been detected in the serum or peritoneal ﬂuid of a group of
ovarian cancer patients in stage I. These TSGs include RASSF1A,
BRCA1, APC, CDKN2A, and DAPK (Ibanez De Caceres et al.,
2004; Table 1). Especially for DAPK methylation, there is a tight
association of the methylation status between DNA isolated from
the peripheral blood and primary tumor (Collins et al., 2006).
Furthermore, epigenetic biomarkers can be applied to strat-
ify patients according to their epigenetic status of ovarian cancer.
Recently, 302 loci spanning 189 promoter CGIs at 137 genes in
the Wnt signaling pathway were analyzed by differential methy-
lation hybridization. Several genes (FZD4, DVL1, NKD1, ROCK1,
AXIN1, LRP5, and NFATC3) involved in the Wnt pathway were
found to be signiﬁcantly associated with progression-free survival
(PFS). Furthermore, NKD1 and DVL1 were shown to associate
with two groups of patients with distinct PFS (Dai et al., 2011).
More recently, an integrated genomic analysis of ovarian carci-
noma was performed by the Network (2011). Four ovarian cancer
transcriptional subtypes, three miRNAs subtypes, four promoter
methylation subtypes, and a transcriptional signature associated
with survival duration were identiﬁed in 489 high-grade serous
ovarian adenocarcinomas.
Genes that are speciﬁcally methylated in ovarian cancer still
wait to be discovered that have the potential to distinguish ovar-
ian cancer from other cancers and to therefore serve diagnostic
purposes. Epigenomics studies consisting of methylomic analysis
may hold the key in this regard. However, multicenter-conducted
studies and well-controlled clinical trials will eventually be needed
to further validate these biomarkers.
EPIGENOMIC STUDIES ON THE CHEMOPREVENTION OF
OVARIAN CANCER
CHEMOTHERAPY AND DRUG RESISTANCE OF OVARIAN CANCER
Currently, the gold standard treatment for ovarian cancer is
surgical excision followed by cytotoxic chemotherapy. Cisplatin
and carboplatin have often been mainstays for treatment of
ovarian cancer. Cisplatin can form interstrand and intrastrand
adducts once it bound to DNA double strands. The adducts
are characterized by DNA bending toward the major groove,
unwinding of the double helix, and alterations of the grooves
and of the puckering of the sugars (Takahara et al., 1995).
Adducts can further be recognized by several proteins of the
DNA damage repair system of the cell and eventually leads
to apoptosis. Although most ovarian cancers respond to ﬁrst-
line chemotherapy, recurrence of ovarian cancer occurs in up
to 75% of the patients (Agarwal and Kaye, 2003). This resis-
tance can be intrinsic or acquired. Intrinsic resistance means
that the resistant cell already exists in the tumor. The hypoth-
esis is that the pretreatment tumors contain certain gene
expression signatures that lead to the resistance. By contrast,
acquired resistance occurs in tumors that generate resistance
after chemotherapy by gene mutation or epigenetic modula-
tion. The nature of cisplatin-mediated chemotherapy (targeted
at DNA) is based on the potential of acquired resistance (caused
by gene mutation) occurring. Cisplatin resistance could be
caused by multiple factors. Generally, those factors could be
pharmacokinetics-related, including cisplatin uptake and efﬂux,
inactivation by thiol-containing molecules, such as glutathione
(gamma-glutamylcysteinylglycine, GSH), or could be caused by
the sensitivity of the target cell toDNAdamage caused by cisplatin,
including an aberrant DNA repair system, change in apopto-
sis pathway, or hyperactivation of oncogenes (Borst et al., 2008;
Figure 2).
Apparently, genetic and epigenetic mechanisms both play
essential roles in these processes. Due to the reversible nature of
epigenetic modulation, it has become a promising target for can-
cer treatment.With the consideration that multiple factors may be
involved in the resistance of ovarian cancer cells to cisplatin treat-
ment, a strategy of targeting those multiple factors simultaneously
may hold the key for this refractory disease. Potential targets for
epigenetic mechanisms on chemotherapy possibly include most of
the key genes involved in the metabolism pathway of chemother-
apy drugs and apoptosis pathway. Epigenomic studies thus may
provide us valuable information on the aberrant epigenetic status
of those genes which could guide specialized therapy.
Several studies had indicated that epigenetic inactivation of
genes involved in trigging an apoptotic response would result in
drug resistance. For instance, MLH1 can recognize certain dam-
ages in DNA which can further activate a cascade response that
can induce apoptosis. Methylation of MLH1 and further tran-
scriptional silencing occurs in cisplatin-resistant ovarian cancer
(Gifford et al., 2004). DAPK,which is a gene involved in apoptosis,
has also been indicated to be silenced in drug resistant cancer
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FIGURE 2 | Potential pathways involved in cisplatin resistance in
ovarian cancer cells. Cisplatin resistance can occur due to the
decrease of proteins that are responsible for its uptake and an
increase of proteins that can transport cisplatin to the outside of a cell.
Cisplatin in the cell can also be inactivated by thiol-containing molecules
(GSH) and cisplatin could cause DNA damage. The DNA repair system
(hMLH1) can then work together with p53 and cell cycle
regulating proteins (p16, p21) to engage G1 and G2 cell cycle arrest.
Depending on the result of DNA repair and the balance between
pro-apoptosis and anti-apoptosis proteins, the cell can either survive or
undergo apoptosis. Targets that could be regulated by epigenetic mechanisms
had been highlighted in red.
due to methylation (Lehmann et al., 2002). In a recent study
by Li et al. (2009) DNA methylation and gene expression were
integrated together to analyze the pathways involved in platinum
resistance in ovarian cancer. This study indicates disruption of
tumor-suppressive functions by hypermethylation, such as cell
adhesion molecules, tight junction formation, PPAR signaling,
and leukocyte transendothelial migration pathways. Signiﬁcant
up-regulation of tumor-promoting cascades by hypomethylation,
such as PIK3K, PDGFRA, E2F1, and TGFBR2, which represents
PI3K/Akt, cell cycle progression, and TGF-beta pathways, was also
reported.
EPIGENOMIC STUDIES ON THE RESENSITIZATION OF OVARIAN CANCER
A number of studies have been performed to investigate the
ability of epigenetic modulating drugs on resensitizing resistant
ovarian cancer to chemotherapy. DNMT inhibitors (DNMTIs)
are analogs of deoxycytosine with different substitutions at their
5-carbons. They can prevent transfer of a methyl moiety by
trapping the methyltransferases once they are incorporated into
DNA (Lyko and Brown, 2005). These inhibitors have been used
to induce re-expression of silenced TSGs caused by hyperme-
thylation. It is hypothesized that reactivation of those genes
could sensitize the apoptotic pathway mediated by chemotherapy.
RASSF1A and hMLH1 up-regulation by decitabine and zebu-
larine, two DNMTIs, has contributed to the resensitization of
cisplatin-resistant ovarian cancer cells to platinum (Balch et al.,
2005).
Histone deacetylation is another recognized mechanism that
contributes to silencing of TSGs in cancer. Histone deacetylation
could lead to a compact conformation of DNA which is not
accessible by DNA transcription factors. HDACIs could inhibit
deacetylation by HDACs, thereby releasing genes from epigenetic
repression. HDACIs have been indicated to induce cell cycle arrest,
differentiation, or apoptosis in cancer cells (Secrist et al., 2003).
The combination of a DNMTI and HDACI to re-sensitize resis-
tant cancer cells has also been investigated. It is hypothesized that
there should be an additive or synergestic effect on silenced TSGs
expression through this approach (Karpf and Jones, 2002). In
studies conducted by Steele et al. (2009) it was shown that a com-
bination of decitabine (a DNMTI) with belinostat (an HDACI)
is more effective in resensitizing ovarian cancer xenografts than
decitabine alone.
Several studies have also demonstrated that miRNAs act as
potential targets for resensitization of ovarian cancer. Liang
et al. (2010) showed miRNA-related genetic polymorphisms may
impact ovarian cancer predisposition and clinical outcome both
individually and jointly. Others showed that low tumoral miR-
200 expression was signiﬁcantly associated with high β-tubulin III
protein content, a trend toward poor PFS (Leskelä et al., 2011).
In a more recent study, Boyerinas found that Let-7 can sensitize
ovarian cancer with acquired resistance to Taxanes via targeting
IMP-1, a protein known to stabilize mRNAs of a number of genes,
which can lead to degradation of the drug resistance gene MDR1
(Boyerinas et al., 2011).
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NATURAL COMPOUNDS AS POTENTIAL EPIGENOMIC MODULATORS TO
RE-SENSITIZE RESISTANT OVARIAN CANCER CELLS
Although conventional epigenetic drugs are promising in treating
cancer, their non-speciﬁc effect could be detrimental to cancer pre-
vention. DNMTIs could lead to genomic hypomethylation which
could result in GI. They could also activate potential oncogenes or
drug resistant genes due to their demethylation effect on the CGIs
of these genes. HDACIs could have a similar effect due to their
non-speciﬁc targets.
A number of natural compounds extracted from plants,
including epigallocatechin-3-gallate (EGCG) from green tea, sul-
foraphane (SFN) from cruciferous vegetables, and genistein from
soybean have been demonstrated to effectively inhibit prolif-
eration of cancer cells via their epigenetic modulating effects.
EGCG has been found to function as a DNMTI to reactivate
TSGs (Fang et al., 2003). It has also been shown to inhibit
telomerase expression in cancer cells through epigenetic remod-
eling of the hTERT promoter (Mittal et al., 2004; Berletch
et al., 2008; Chen et al., 2009; Meeran et al., 2011). The
advantage of these natural compounds compared with conven-
tional epigenetic modulators is their low toxic effect to nor-
mal cells. Furthermore, a combination of these natural com-
pounds may exert additive or synergistic effects in killing can-
cer cells which would allow yet lower and safer doses to be
applied. Epigenomic studies on the epigenetic alterations of
genes in response to treatment with natural compounds may
reveal potential mechanisms for how these compounds exert their
extra beneﬁts and which could guide design of future anticancer
drugs.
SUMMARY
Epigenetic regulation of gene expression plays a fundamental role
in normal tissue as well as diseases. Previous epigenetic studies
focused on individual genes have provided us with a wealth of
insights into the mechanisms of ovarian cancer. In this review,
we summarized most of the related progress on epigenomics of
ovarian cancer, including its development, potential biomarker,
chemoresistance, and possible treatment on its resensitization.
To understand this complex disease comprehensively, there is an
urgent need to reveal the epigenetic status genome-wide (epige-
nomics) in ovarian cancer. Numerous pathways involved in basic
cellmetabolismhavebeendemonstrated tobe aberrantly regulated
by epigenetic mechanisms during the progression of ovarian can-
cer, such as Wnt, TGF-beta, cell cycle regulation, and the apoptosis
pathway. Although considerable progress has been made on the
understanding of the nature of ovarian cancer epigenomics, espe-
cially of DNA methylation, more effort is still needed, speciﬁcally
on histone modiﬁcations and miRNA-related epigenomics under-
lying the development of different stages and chemoresistance of
ovarian cancer. Knowledge in this regard will undoubtedly pro-
mote the development of novel biomarkers and lead to the design
of more effective epigenetically based chemotherapy. As ovarian
cancer patients have already begun to beneﬁt from studies in this
ﬁeld, continued efforts in this direction would be justiﬁed.
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